
ICON (ICLR) Stock Forecast & Price Target
ICON (ICLR) Analyst Ratings
Bulls say
Icon has demonstrated robust growth with a 11% sequential increase in gross business awards, reflecting significant wins from biotech clients and ongoing advancement in partnerships with large pharmaceutical companies. The company has surpassed its financial targets related to the PRA acquisition, positioning itself favorably against funding environment uncertainties while also capitalizing on a favorable client and business mix. With the increasing demand for clinical trial services in the expanding contract research organization market, Icon is well-situated to accelerate its research capabilities.
Bears say
The financial outlook for Icon has become increasingly concerning, primarily due to revised EBITDA margin expectations that have decreased from approximately 20% to the high-19% range for both the current year and 2025. Additionally, the company faces significant downside risks that include slowed clinical trial activity stemming from pharmaceutical industry reprioritizations, uncertainties surrounding biotech funding, and inflationary pressures impacting operational costs. These factors collectively contribute to an atmosphere of uncertainty regarding Icon's future revenue growth and profitability.
This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.
ICON (ICLR) Analyst Forecast & Price Prediction
Start investing in ICON (ICLR)
Order type
Buy in
Order amount
Est. shares
0 shares